Figure 1: On-site Photo of the Night of Chinese Pharmaceutical Innovation and Development

On November 3, 2023, the 15th China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference 2023, hosted by the China Pharmaceutical Enterprises Association, the China Medicinal Biotech Association, the Hangzhou Investment Promotion Bureau, and the Hangzhou Linping District Bureau of Commerce, and organized by Healthcare Executive and H50, was grandly held in Hangzhou. As a high-level and highly influential event in the industry, it upholds the mission of empowering the transformation and upgrading of China's pharmaceutical industry, bringing together entrepreneurs, scientists, and investors, aiming to integrate various elements such as government, enterprises, technology, capital, and clinical practice, focusing on building an innovation docking platform and an industrial ecological value linkage platform based on "value". On November 2, during the Night of Chinese Pharmaceutical Innovation and Development, the "Top 100 Life Science Service Enterprises List" was released. In this selection, R&G, with its brand reputation, high-quality service standards, and excellent customer satisfaction, was listed on the ranking. Mr. Qiao Yuhang, Senior Director of Clinical Operations at R&G, attended the event on behalf of the company and went on stage to receive the award.

Figure 2: Mr. Qiao Yuhang (fourth from left), Senior Director of Clinical Operations at R&G, receiving the award on behalf of the company

This "Top 100 Life Science Service Enterprises" selection focuses on life science service enterprises serving pharmaceutical innovation and pharmaceutical innovation CXO enterprises (CRO, CDMO), with market value (valuation) and customer coverage as the main evaluation criteria. Using a sampling survey method, the judges invited R&D, production, quality, and other relevant director-level leaders from 40 representative enterprises in the industry, including Qilu Pharmaceutical, Hengrui Pharmaceuticals, etc., to conduct surveys on three dimensions of the participating enterprises: brand awareness (50%), cost-effectiveness of cooperation (30%), and service satisfaction (20%), and the final results were comprehensively derived.

This is the second time R&G has received this honor after being awarded in 2022. This recognition is an affirmation and encouragement of R&G's ongoing deep commitment in the field of new drug research and development. As a publicly listed CRO company focusing on the clinical stage, R&G will continue to leverage its innovative and scientific technological advantages in future development, using scientific methods to solve problems encountered by clients in clinical research and development, reduce R&D risks, accelerate product launches, continuously promote the development of innovative drugs in China, make greater contributions to human health and well-being, and continually practice the noble corporate vision of "All for Health."